Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07689175 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Name: Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma — clinical trial record (NCT07689175)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorUniversity of Texas Southwestern Medical Center

Started2026-08-21

View on ClinicalTrials.gov ↗

Amendment history

2026-08-21

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-10-31→confirmed 2026-08-21

Study sitesdetails revised at 1 of 1 site

2026-06-30

Original filing

University of Texas Southwestern Medical Center

297 trials monitored

See 22 trials at risk

Liver Cancer

1,505 trials monitored

See 60 trials at risk

The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.

Trial Details

NCT Number	NCT07689175
Lead Sponsor	University of Texas Southwestern Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	60 participants
Start Date	2026-08-21
Primary Completion	2031-10-31 (estimated)
Study Completion	2032-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-25